Other Clinical Trial - Steroid Withdrawal in Pediatric Renal Transplant:

Status Completed

Clinical Trial Summary

The present study investigates the safety and efficacy of steroid withdrawal at six days post-transplant in pediatric renal recipients under concomitant immunosuppression based on antibodies anti IL2 (interleukin 2), Tacrolimus (TAC) and Mycophenolate Mofetil (MMF). To investigate the impact of this protocol in growth, bone metabolism, insulin- sensitivity and evaluate the expression of IL17 (interleukin 17) and mRNA FOXP3 (messenger ribonucleic acid forkhead box protein 3) as early markers of acute rejection (blood, urine and renal biopsy).

Hypothesis:Steroid withdrawal in renal pediatric transplant patients improves growth and bone metabolism without increasing the risk of acute rejection. The expression of FoxP3/IL17 in urine cells could be an early molecular markers of acute rejection.

Clinical Trial Description

The intention of this investigation is to evaluate a prospective immunosuppressive protocol based on antibodies anti IL-2 (Ac-IL-2), Tacrolimus (TAC) and Mycophenolate Mofetil (MMF)and withdrawal steroids in renal transplant and to compare with a steroid-based protocol.

Objectives:

1. To evaluate growth and the impairment in the GH/IGF (growth hormone/insulin like growth factor) axis

2. To determine the impact of steroids on bone metabolism (biochemical parameters, DXA and pQCT)

3. To determine the steroid effect on metabolic factors (dyslipidemia, insulin- sensitivity and arterial hypertension)

4. To determine acute rejection incidence (protocol renal biopsy)

5. To evaluate the expression of IL-17 and mRNA FoxP3 as early markers of acute rejection (blood, urine and renal biopsy).

Two treatment regimes (Arms)will be compared in randomized form in the course of 12 months after transplantation.

Arm A: TAC + MMF + withdrawal of steroids over a six-days following randomization.

Arm B: TAC + MMF + prednisolone (see schedule)/day ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Kidney Diseases

Clinical Trial Details

NCT number	NCT00707759
Study type	Interventional
Source	Fondo Nacional de Desarrollo Científico y Tecnológico, Chile
Contact
Status	Completed
Phase	Phase 3
Start date	June 2008
Completion date	December 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03246984` - VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ	N/A
Completed	`NCT03545113` - Graft-first Versus Fistula-first in Older Patients With End-stage Kidney Disease	N/A
Recruiting	`NCT05100017` - Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure	N/A
Recruiting	`NCT04559321` - Holmium Vs Trilogy Kidney Stones GUY's 1-2	Phase 3
Recruiting	`NCT05036850` - China Kidney Patient Trials Network
Completed	`NCT04037436` - Functional Exercise and Nutrition Education Program for Older Adults	N/A
Active, not recruiting	`NCT01529658` - Renal Hypothermia During Partial Nephrectomy	N/A
Completed	`NCT01679587` - Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY85-3934 in Subjects With Chronic Kidney Disease (CKD)	Phase 1
Completed	`NCT01155141` - Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH	Phase 4
Completed	`NCT00755690` - Study of Dietary Phosphate and Mineral Homeostasis in Early Chronic Kidney Disease	N/A
Recruiting	`NCT05759754` - Effects of Traditional Chinese Medicine (GSJYF) in Children With Inherited Proteinuric Kidney Disease	N/A
Completed	`NCT03213158` - Ixazomib for Desensitization	Phase 2
Active, not recruiting	`NCT02237352` - Mechanisms of Diabetic Nephropathy in Ecuador
Recruiting	`NCT06067867` - Kidney and Pregnancy Registry
Recruiting	`NCT04110080` - Enhanced Recovery After Surgery in Kidney Transplant Donors	N/A
Active, not recruiting	`NCT04876963` - HOLT-ED: Holter-monitoring in End-stage Renal Disease
Enrolling by invitation	`NCT05324878` - Honoring Individual Goals and Hopes: Implementing Advance Care Planning for Persons With Kidney Disease on Dialysis
Not yet recruiting	`NCT03899298` - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions	Phase 1
Active, not recruiting	`NCT04631965` - Healthcare Transition of Adolescents With Chronic Health Conditions
Completed	`NCT03394859` - Electronic Medical Records and Genomics (eMERGE) Phase III

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Steroid Withdrawal in Pediatric Renal Transplant: Impact on Growth, Bone Metabolism and Acute Rejection

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms